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Background: The relative frequencies of demyelinating diseases among Korean patients with idiopathic inflammatory
demyelinating disease of the central nervous system (IIDD) have not been sufficiently studied. We therefore describe a
cohort of 203 patients with IIDD from three centers in Korea whose syndromes were identified precisely according to
international clinical criteria and autoantibody to aquaporin 4 (AQP4-Ab) status.
Methods: In total, 260 consecutive patients were screened and 203 were included from three hospitals in Korea.
All were tested for AQP4-Ab by using a cell-based assay. Patients who met the criteria for definite neuromyelitis
optica (NMO) or had a positive AQP4-Ab test result were defined as the NMO group. Among the others, patients
were assessed if they had acute disseminated encephalomyelitis, multiple sclerosis (MS), acute transverse myelitis,
optic neuritis, or other demyelinating disease as a clinically isolated syndrome of the brain.
Results: Eighteen percent of patients were classified as the NMO group, 2% as acute disseminated encephalomyelitis,
18% as MS, 41% as acute transverse myelitis, 11% as optic neuritis, and 8% as other clinically isolated syndrome of the
brain. AQP4-Ab was positive in 18% of patients and the relative frequency of NMO to MS (NMO/MS ratio) was 1.06.
The mean duration of follow up in our patients was 64 months.
Conclusions: Among Korean patients with idiopathic inflammatory demyelinating diseases, the incidence of NMO
may be similar to that of MS, and the overall positivity of AQP4-Ab could be lower than previously reported. In addition,
acute transverse myelitis that is not associated with MS or NMO can be relatively common in these patients. Further
population-based studies with AQP4-Ab are needed to determine the exact incidence of NMO and other idiopathic
inflammatory demyelinating diseases in Korea.
Keywords: Neuromyelitis optica, Multiple sclerosis, Anti-aquaporin-4 antibody, Idiopathic inflammatory demyelinating
disease of the central nervous system, KoreanBackground
Idiopathic inflammatory demyelinating disease of the
central nervous system (IIDD) refers to a wide spectrum
of disease entities that mostly consist of multiple sclerosis
(MS) [1], neuromyelitis optica (NMO) [2,3], acute dissem-
inated encephalomyelitis (ADEM) [4], acute transverse
myelitis (ATM) [5], and optic neuritis (ON) [6].* Correspondence: pks1126@chol.com
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unless otherwise stated.NMO is distinguished from MS by the presence in
the serum of a pathogenic autoantibody to aquaporin-4
(AQP4-Ab) [7], by severe optic and spinal attacks [8],
and by the presence of a severely disrupted blood–brain
barrier [9]. The relative frequency of NMO to that of MS
(NMO/MS ratio) was previously reported to be high in
Thailand (1.4) [10] and Japan (0.29–0.59) [11,12], com-
pared to that in Europe (0.024) [13] and Latin America
(0.073–0.26) [14].
However, the NMO/MS ratio, as well as the relative
frequencies of other demyelinating diseases such as ADEM,. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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not been sufficiently studied.
The aim of this study was to describe a cohort of 203
patients from three centers in Korea with IIDD of the




In total, 260 consecutive patients who were suspected as
having IIDDs such as definite NMO, NMO spectrum
disorder (NMOSD) [2,3], ADEM [4], MS [1], ATM [5],
ON [6], or a clinically isolated syndrome (CIS) of the brain
[15] and whose serum was tested at the John Radcliffe
Hospital, Oxford, were screened [16].
All provided written consent and visited Seoul National
University Hospital or Seoul National University Bundang
Hospital between September 1, 2009, and June 30, 2012,
or Seoul Medical Center between March 1, 2011, and June
30, 2012. Excluded were patients who had incomplete
medical records (n = 3), no magnetic resonance imaging
(MRI) data (n = 2), were diagnosed with diseases other
than IIDDs (such as infectious, vascular, tumorous, degen-
erative, or metabolic conditions; n = 48), were referred
from a foreign hospital (n = 1), or were followed for less
than 6 months (n = 3). In total, 203 patients were finally
included in the study; the duration of their follow-up was
64.42 ± 60.03 months (mean ± standard deviation).
Classification of patients
We evaluated the diagnoses of patients using the following
steps:
Step 1: Identification of patients who met the revised
diagnostic criteria for definite NMO [2].
Step 2: Patients who did not meet the diagnostic
criteria for NMO [2] were dichotomized according to
their test results for AQP4-Ab. Those with positive test
results were included in the NMO group, and were
assessed if they had the clinical features of NMOSD
[3]. These features included 1) longitudinally extensive
myelitis involving three or more vertebral segments,
2) ON with recurrent or simultaneous bilateral events,
and 3) ON or myelitis associated with symptomatic
brain lesions typical of NMO [3]. Consistent with
recent recommendations [1], the criteria for
opticospinal MS [11] were not included.
Step 3: Assessment of patients to determine whether
they met the proposed criteria for ADEM [4], among
those who were found not to have AQP4-Ab in the
above step.
Step 4: Assessment of patients who did not fulfill the
above criteria, using the 2010 international panel
diagnostic criteria for MS [1].Step 5: Assessment of patients who did not meet any of
the above criteria to determine whether they had a
clinically isolated syndrome of the brain [17], ATM
[18-20], or ON [6].
AQP4-Ab testing
Sera were taken, immediately centrifuged, and stored
at −80°C, according to standard protocols [21]. They were
tested for the presence of AQP4-Ab at the John Radcliffe
Hospital, Oxford, UK using a cell-based assay (CBA) with
recombinant AQP4, as described previously [22,23].
Standard protocol approval, registration, and patient
consent
This study was approved by the Seoul National University
Bundang Hospital (IRB number: B-1007-105-401) and
Seoul National University Hospital Institutional Review
Board (IRB number: H-1012-023-317). All patients pro-
vided written informed consent before participating.
Results
Number of patients and AQP4-Ab–positive cases in the
individual disease groups
Of the 203 patients with IIDDs, 17 met the revised diag-
nostic criteria for definite NMO [2] and 16 (94%) of
these patients had positive AQP4-Ab test results [2].
Twenty-one patients who did not meet the NMO criteria
also had positive AQP4-Ab test results, nineteen of whom
showed clinical features of NMOSD. Two patients with
positive AQP4-Ab test results did not have the clinical
features of NMOSD. One of these patients had symptoms
of diplopia and an isolated brain lesion involving the
AQP4-rich periaqueductal area [24], and the other had
recurrent mild symptoms and signs of myelitis (e.g.
hypesthesia, pain in lower extremities, voiding difficulty,
hyper-reflexive deep tendon reflex) but no definite lesion
that could be seen on repeated spinal MRI.
Of the 165 patients who did not meet the revised diag-
nostic criteria for definite NMO [2] and did not have
AQP4-Ab, 3 met the proposed criteria for ADEM [4]
and 36 met the International Panel criteria for MS [1].
All of our patients with ADEM were monophasic with a
mean follow up duration of 26.8 months, and had no oli-
goclonal band.
Of the remaining patients, 19 had clinically isolated
syndrome of the brain, 84 had ATM, and 23 had ON.
The ATM cases without evidence of either NMO or MS
consisted of 50 patients with longitudinally extensive
transverse myelitis (LETM) and 34 patients with acute
partial transverse myelitis (APTM). The mean age at
onset was 44.73 ± 13.90 y, 64 patients (76%) were male,
and the follow up duration was 45.95 ± 38.73 months.
The relative incidence of these patients was high, being
41.4% (84 out of 203) of our cohort.
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positivity [25] was 18.2% in our Korean cohort with
IIDDs (Figure 1).
Ratio of NMO to MS in Korean IIDD
The number of patients in our NMO group was 38,
including 17 patients with definite NMO and 21 AQP4-
Ab–positive patients with or without the clinical features
of NMOSD. Therefore, the NMO/MS ratio was 1.06 (38/
36) in our cohort (Figure 1).
Discussion
The present study revealed the following findings in 203
Korean patients with IIDDs from three major hospitals.
(1) In our cohort, the NMO/MS ratio was 1.06, which
implies that the number of patients with NMO was
almost the same as the number with MS. (2) The
AQP4-Ab test was positive in 18.2% of Korean patients
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Figure 1 Diagnostic flow and AQP4-Ab positivity in individual groups
APTM = acute partial transverse myelitis, AQP-Ab = aquaporin-4 autoantibody
inflammatory demyelinating diseases of the central nervous system, LETM= lon
MS =multiple sclerosis, myelitis and brain =myelitis associated with symptomat
NMOSD= neuromyelitis-optica spectrum disorder, ON = optic neuritis, r/blON=was common in Korean patients with IIDD and accounted
for 41% of these patients.
The NMO/MS ratio was 1.06 in our Korean cohort
and was higher than that in a Danish population (0.024)
[26] and in a Japanese study (0.29–0.59) [11,12]. Com-
bining our figure for the ratio with the prevalence of MS
in Korea (3.5–3.6 cases per 100,000 individuals) [27]
may enable us to estimate the crude prevalence of NMO
in Korea. However, additional population-based studies
are needed to determine the exact values.
As expected, the overall AQP4-Ab positivity among our
Korean patients with IIDDs (18.2%) was higher than that
among Caucasian populations (1.7–7.2%) [26,28], which
may be due to the higher incidence of MS in Caucasian
patients with IIDDs (50.8–80%) [26,28] compared to that
in our sample (17.7%). However, our AQP4-Ab positivity
rate was much lower than the previously reported high
AQP4 positivity rate in single-center studies in Thailand
(39.3%) [10] and Korea (33%) [29], which could have beenfinite NMO (n=17, AQP4-Ab was positive in 16)
Incomplete medical record (n=3)
No magnetic resonance imaging (n=2)
Disease other than IIDD (n=48),
Patient referred from foreign hospital (n=1)
Followed less than 6 months (n=3)
Excluded 
n = 57
Total AQP4-Ab positive 
cases = 37 / 203 (18.2%)
AQP4-Ab positive (n =21)
Without clinical feature of 
NMOSD (n = 2)
- isolated brainstem lesion (n = 1)
- recurrent symptoms and signs of myelitis 
without definite lesions on MRI (n = 1)
ical feature of NMOSD 
 19)
LETM (n = 12, 9 were recurrent)
r/bON (n = 3)
yelitis & brain (n = 4)
 23)   
phasic ON (n = 10)
 (n = 13)
. Abbreviations: ADEM = acute disseminated encephalomyelitis,
, CIS, brain = clinically isolated syndrome of the brain, IIDDs = idiopathic
gitudinally extensive transverse myelitis, MRI =magnetic resonance imaging,
ic brain lesions typical of NMO, n = number, NMO= neuromyelitis optica,
recurrent or bilaterally simultaneous optic neuritis.
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of those studies [25].
In our cohort, the incidence of ATM patients without
evidence of NMO or MS was high (43.8%). The exact
cause of this phenomenon is not clear. However, it could
be related to one or more of the following: First, the
prevalence of MS was reported to be low (3.5–3.6/
100,000) in Korea [27], compared to that in Western
countries (>150/100,000 in northern Europe) [30]. This
makes the incidence of MS among Korean patients with
IIDD relatively low, which in turn, could have brought
about the relatively high incidence of other IIDDs, such
as ATM, in our cohort. Second, although we have
adopted a highly sensitive assay method for AQP4-Ab
that uses recombinant AQP4 antigen, a recent study has
shown that using a combination of different assays and/
or retesting can improve the sensitivity of the AQP4-Ab
test in a small number of patients [31]. Therefore, we
speculate that a minor portion of our patients with
ATM could have been more accurately diagnosed as
having NMO with the use of combination assay methods
or serial retesting. Third, the observed difference in
ATM incidence could have been due to a difference in
genetic susceptibility between Asians and Caucasians [32].
Fourth, some of these patients with ATM might have been
diagnosed as having MS with a longer period of follow-up.
However, because the mean duration of follow-up in our
study was already relatively long, 64.42 months, it does
not seem that a major portion of these ATM patients
would have been diagnosed with MS with still longer
periods of follow-up. Lastly, myelin-oligodendrocyte
glycoprotein (MOG) antibody has recently been found
in patients with demyelinating diseases of the CNS,
including LETM. We speculate that at least some of our
patients with ATM are associated with MOG antibody
[33]. Further study is needed to determine the exact cause
of this relatively high incidence of ATM among Koreans.
The current criteria for definite NMO [2] and the clinical
features of NMOSD [3] seem to be useful in screening
for NMO, because most of our patients in NMO groups
met these criteria and/or had those clinical features.
However, in our cohort, the criteria still seem to have
some limitations, as follows: 1) Fifty patients with LETM
(25% of our demyelinating cohort) and thirteen patients
with bilateral simultaneous or recurrent optic neuritis (7%
of our demyelinating cohort) did not have AQP4-Ab. This
showed that the clinical features of NMOSD are not
specific for NMO, at least in Asians. 2) A small number
of patients (n = 2, 5.4% of our NMO group), who did not
show these clinical features, still showed positive AQP4-Ab
assay results (Figure 1). This result is in accord with recent
studies evaluating the diagnostic utility of these clinical
features [34,35]. Thus, despite the current diagnostic
criteria and clinical features of NMOSD [2,3] seemingto be useful, they still appear to require further revisions,
especially if they will be applied to Asians.
Our study has several limitations. First, it was not a
population-based study. However, it involved a relatively
large number of consecutive patients from three major
hospitals in Korea, in the assessment of AQP4-Ab posi-
tivity and the ratio of NMO to MS in Korean patients
with IIDDs. Second, some patients with AQP4-Ab can
manifest isolated brain lesions in the early stages of the
disease [36], which was not included in our list of clinical
features of NMOSD. This is because we have adapted
the published diagnostic criteria or clinical features of
NMOSD [2,3]. However, some patients with isolated
cerebral involvement and AQP4-Ab can show the same
clinical course and/or response to treatment as do those
with definite NMO [37].
Conclusions
The incidence of NMO may be similar to that of MS in
Korean patients with IIDDs. The AQP4-Ab positivity
was 18.2% in our multi-center cohort of Korean patients
with IIDDs, which is much lower than that reported pre-
viously from single-center studies in Asia (33–39%)
[10,37]. ATM not associated with NMO or MS could be
found in more than 40% of our patients with IIDDs,
which mainly seems to be due to the low prevalence of
MS in Korea. Additional population-based studies with
AQP4-Ab testing are needed to determine the exact
incidence of NMO, as well as the other diverse types of
IIDDs, in Korea.
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